Menopause

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Bayer's OASIS 3 trial affirmsed the safety and efficacy of elinzanetant in reducing moderate to severe vasomotor symptoms, bolstering confidence in its potential as a non-hormonal solution for menopause-related issues.

Delve into the connection between nighttime vasomotor symptoms and Alzheimer's disease risk in women, shedding light on potential modifiable factors impacting cognitive health.

Discover how the early transition to menopause can affect women's work ability and workforce participation, shedding light on crucial considerations for both healthcare providers and employers.

Discover how neighborhood disadvantage affects menopause onset and implications for women's health, as revealed by recent research published in Menopause, the journal of The Menopause Society.

A recent study revealed that adherence to plant-based diets among postmenopausal women does not correlate with hip fracture risk, challenging concerns about the impact of such diets on bone health.

A recent investigation sheds light on the efficacy of hormone therapy in alleviating depressive symptoms associated with menopause, revealing potential benefits for women undergoing natural menopause.

A recent study found that COVID-19 vaccination is not associated with an increase in incident postmenopausal bleeding diagnoses, providing reassurance to providers and patients concerned about bleeding caused by the vaccine.

Bayer has initiated the phase 2 trial NIRVANA to evaluate elinzanetant's potential in treating sleep disturbances in menopausal women, addressing a prevalent yet unmet need in women's health.

Elinzanetant demonstrated positive safety and efficacy data in managing menopausal vasomotor symptoms, highlighting its potential as a treatment for improving women's quality of life during menopause.

A recent study in Menopause, the journal of The Menopause Society, suggests that a longer reproductive life span and later age at menopause may be associated with a reduced risk of low handgrip strength in postmenopausal women.

In a recent study, therapeutic touch and music independently improved sleep quality in perimenopausal and postmenopausal women.

This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.

In a recent study, women with worse mental and gastrointestinal health had stronger menopausal symptoms.

In a recent study, increased hair cortisol levels were effective at measuring worsened cognitive health in perimenopausal women.

In a recent study, hot flashes were indicated to be an underlying risk factor for cardiovascular disease.

In a recent study, variations in physiology during aging were found between male and female participants.

Commons forms of osteoarthritis, as well as prevention methods, were discussed at The Menopause Society 2023 annual conference.

The most recommended and non-recommended methods of nonhormone therapy for treatment of vasomotor symptoms were discussed at The Menopause Society 2023 Annual Conference.

Advancements in technology used to measure bone health in postmenopausal women were discussed at the Menopause Society 2023 Annual Meeting.

A recent study measuring sexual functioning in women with post-traumatic stress disorder was discussed at The Menopause Society 2023 Annual Meeting.

In a recent study highlighted at the Menopause Society 2023 Annual Meeting, a correlation was found between the number of hot flashes experienced and the risk of Alzheimer’s disease among perimenopausal and postmenopausal women.

A correlation between brown adipose tissue activity and hot flashes was discussed at the Menopause Society 2023 Annual Conference.

In a recent study, increased use of cannabis to manage menopause symptoms was observed among midlife women.

In a recent study highlighted at The Menopause Society 2023 Annual Meeting, White women with a psychiatric condition were 40% more likely to receive a hormone therapy prescription than Black women.

At The Menopause Society 2023 Annual Meeting, tips on reducing weight during menopause will be discussed.

The presence of NAFLD increased from 25.3% to 29.4% among patients receiving oral menopause hormone therapy.

In a recent study, women with premenstrual disorders were more likely to experience early menopause and vasomotor symptoms.

A recent survey indicated a lack of proper menopause education for obstetricians and gynecologists.

Daré Bioscience has published the results of a phase ½ trial on DARE-HRT1, indicating efficacy against moderate-to-severe vasomotor symptoms.